Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. - Wikidata - awgldk - TriplyDB

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.

http://www.wikidata.org/entity/Q37356185

about

Biomarkers in triple negative breast cancer: A review Triple negative breast cancer: an Indian perspective.Triple negative breast cancer - our experience and review Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review.

P2860

Q26775094-0F1E18FB-70E4-4865-B353-42692E66BC4B Q35974277-A6606239-2D37-45BF-9775-F7F3FA8EF7DF Q36024205-0C3F919C-ED5C-47FA-A565-07844728CBF9 Q37319292-77589E68-1B73-4D10-B264-C9E01FF8268E

P2860

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.

http://www.wikidata.org/entity/Q37356185

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.

@en

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.

@nl

type

label

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.

@en

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.

@nl

prefLabel

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.

@en

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.

@nl

P1433

Q37356185-F2B5335F-E676-4D81-BC74-D13F03B842C9

P1476

Q37356185-8479A8FC-50C7-4440-889C-366F137B25F7

P2093

Q37356185-21A74A97-3407-4A2E-91D5-93FED701D2EF

Q37356185-4A59E48B-9C9E-42E7-8225-FB212F29EE8F

Q37356185-CB4BDAA9-EAD1-4053-A94D-412E1889167A

Q37356185-E767093E-BCAA-4D57-B0D1-BDA0DB1A5538

P2860

Q37356185-09D0B1F7-C970-4C79-B978-8944BBAA8FEE

Q37356185-2C8EAD88-97A3-46A6-8AF5-A5C6B015CF63

Q37356185-312A0DCA-12EC-4BED-8FBF-1D545A741E9F

Q37356185-3EB8EB6A-C669-45E5-94BB-687265383731

Q37356185-40059CBE-0B51-4ACC-A3C0-580E5F1385E3

Q37356185-56547BCA-1049-4214-A5AE-950FDA3ECB26

Q37356185-5B18C562-9A82-47E7-86C3-EE510D089764

Q37356185-5FECF496-793F-4469-964A-2544F529F6AA

Q37356185-6062FC8A-1031-4F9D-852A-D9B80EE58B1A

Q37356185-70DD037B-E2A7-4EFE-95D2-088AE0C88386

P304

Q37356185-B11D9D8D-5272-4324-BC20-93C8591CF3BD

P31

Q37356185-CE492AAD-6A21-439B-8E00-481534D86101

P356

Q37356185-645D566E-B53E-4270-A52F-6C0055BB191F

P478

Q37356185-33A53414-0843-4450-AA02-6D7209242289

P577

Q37356185-A43B9663-7506-46C6-8622-CCA192B2FEFE

P5875

Q37356185-6D9E41F6-14EA-4ED4-A8D1-976B694E277B

P698

Q37356185-968F0934-9901-4A58-906C-8F45ABDAB798

P921

Q37356185-DAB0C97E-7A9F-4049-A7FB-5F19800B4705

P932

Q37356185-CB1D8640-002C-4380-8829-856DAF297061

P356

P1433

Breast Cancer: Targets and Therapy

P1476

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.

@en

P2093

Amit V Patil

http://www.w3.org/2001/XMLSchema#string

Prakash D Gurav

http://www.w3.org/2001/XMLSchema#string

Rajeev Singhai

http://www.w3.org/2001/XMLSchema#string

Vinayak W Patil

http://www.w3.org/2001/XMLSchema#string

P2860

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Repeated observation of breast tumor subtypes in independent gene expression data sets

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Hallmarks of 'BRCAness' in sporadic cancers

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

P304

9-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BCTT.S17094

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259456795

http://www.w3.org/2001/XMLSchema#string

P698

24367172

http://www.w3.org/2001/XMLSchema#string

P921

P932

3846824

http://www.w3.org/2001/XMLSchema#string